Acquired by Aadi Bioscience in August 2021
ARPO - Aerpio Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cincinnati,
United States
Type: Equity
ARPO price evolution
ARPO
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $36.84 | $39.03 | $42.62 | $47.3 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $37.39 | $41 | $44.72 | $49.58 |
| Long term investments | ||||
| Property, plant & equipment | $0.01 | $0.14 | $0.19 | $0.23 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.03 | $0.16 | $0.21 | $0.25 |
| Total investments | ||||
| Total assets | $37.42 | $41.16 | $44.92 | $49.83 |
| Current liabilities | ||||
| Accounts payable | $2.2 | $2.09 | $1.8 | $2.42 |
| Deferred revenue | ||||
| Short long term debt | $0.01 | $0.04 | $0.07 | $0.09 |
| Total current liabilities | $2.21 | $2.13 | $1.87 | $2.51 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.01 | $0.04 | $0.07 | $0.09 |
| Total liabilities | $2.21 | $2.13 | $1.87 | $2.51 |
| Shareholders' equity | ||||
| Retained earnings | -$155.4 | -$150.99 | -$146.55 | -$141.83 |
| Other shareholder equity | $0 | $0 | ||
| Total shareholder equity | $35.22 | $39.03 | $43.06 | $47.32 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $42.62 | $38.56 | $62.65 | $20.29 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $44.72 | $39.57 | $63.98 | $20.9 |
| Long term investments | ||||
| Property, plant & equipment | $0.19 | $0.33 | $0.1 | $0.11 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.21 | $0.37 | $0.14 | $0.13 |
| Total investments | ||||
| Total assets | $44.92 | $39.94 | $64.12 | $21.03 |
| Current liabilities | ||||
| Accounts payable | $1.8 | $3.23 | $5.46 | $3.59 |
| Deferred revenue | ||||
| Short long term debt | $0.07 | $0.1 | ||
| Total current liabilities | $1.87 | $3.33 | $5.46 | $3.59 |
| Long term debt | $0.07 | |||
| Total noncurrent liabilities | $0.07 | |||
| Total debt | $0.07 | $0.17 | ||
| Total liabilities | $1.87 | $3.4 | $5.46 | $3.59 |
| Shareholders' equity | ||||
| Retained earnings | -$146.55 | -$142.24 | -$118.96 | -$108.56 |
| Other shareholder equity | -$0 | $0 | ||
| Total shareholder equity | $43.06 | $36.54 | $58.67 | $17.44 |
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.72 | $2.23 | $3.23 | $3.99 |
| Selling, general & administrative | $4.05 | $2.14 | $2.41 | $1.88 |
| Total operating expenses | $4.77 | $5.6 | $5.64 | $5.86 |
| Operating income | -$4.77 | -$5.6 | -$5.64 | -$5.86 |
| Income from continuing operations | ||||
| EBIT | -$4.41 | -$4.44 | -$4.72 | -$4.96 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$4.41 | -$4.44 | -$4.72 | -$4.96 |
| Income (for common shares) | -$4.41 | -$4.44 | -$4.72 | -$4.96 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15 | $20.16 | ||
| Cost of revenue | ||||
| Gross Profit | $15 | $20.16 | ||
| Operating activities | ||||
| Research & development | $12.59 | $12.82 | $17.85 | $12.15 |
| Selling, general & administrative | $8.76 | $9.76 | $13.49 | $9.24 |
| Total operating expenses | $21.36 | $24.44 | $31.34 | $21.39 |
| Operating income | -$6.36 | -$24.44 | -$11.18 | -$21.39 |
| Income from continuing operations | ||||
| EBIT | -$4.32 | -$23.27 | -$11.17 | -$21.29 |
| Income tax expense | ||||
| Interest expense | -$0.78 | $0.11 | ||
| Net income | ||||
| Net income | -$4.32 | -$23.27 | -$10.4 | -$21.4 |
| Income (for common shares) | -$4.32 | -$23.27 | -$10.4 | -$22.34 |
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Net income | -$4.41 | -$4.44 | -$4.72 | -$4.96 |
| Operating activities | ||||
| Depreciation | $0.01 | $0.02 | $0.02 | $0.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.56 | $0.35 | $0.31 | $0.33 |
| Total cash flows from operations | -$2.23 | -$3.67 | -$4.82 | -$6.92 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | |||
| Investments | ||||
| Total cash flows from investing | -$0.02 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.07 | $0.14 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.03 | $0.07 | $0.14 | $9.34 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.19 | -$3.6 | -$4.68 | $2.42 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | -$4.32 | -$23.27 | -$10.4 | -$21.4 |
| Operating activities | ||||
| Depreciation | $0.06 | $0.08 | $0.05 | $0.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.28 | $1.09 | $3.43 | $0.65 |
| Total cash flows from operations | -$5.38 | -$23.85 | -$5.81 | -$18.88 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.24 | -$0.04 | -$0.01 |
| Investments | $0.05 | |||
| Total cash flows from investing | -$0.02 | -$0.24 | -$0.04 | $0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $9.48 | $48.2 | $37.2 | |
| Net borrowings | $0.3 | |||
| Total cash flows from financing | $9.48 | $9.48 | $48.2 | $37.5 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $4.08 | -$24.09 | $42.35 | $18.65 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 47.66M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$18.46M |
| EBIT | -$18.52M |
| Net Income | -$18.52M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -100.00% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 0.74 |
| Cash/Share | 0.77 |
| EPS | -$0.39 |
|---|---|
| ROA | -42.74% |
| ROE | -45.01% |
| Debt/Equity | 0.04 |
|---|---|
| Net debt/EBITDA | 1.88 |
| Current ratio | 16.94 |
| Quick ratio | 16.94 |